

FORM 7

MONTHLY PROGRESS REPORT

Name of Listed Issuer: Bluma Wellness Inc. (“**Bluma Wellness**” or the “**Issuer**”).

Trading Symbol: BWEL.U

Number of Outstanding Listed Securities: 164,482,690 common shares in the capital of the Issuer (each, a “Common Share”).

Date: March 5, 2021

This Monthly Progress Report must be posted before the opening of trading on the fifth trading day of each month. This report is not intended to replace the Issuer’s obligation to separately report material information forthwith upon the information becoming known to management or to post the forms required by Exchange Policies. If material information became known and was reported during the preceding month to which this report relates, this report should refer to the material information, the news release date and the posting date on the Exchange website.

This report is intended to keep investors and the market informed of the Issuer’s ongoing business and management activities that occurred during the preceding month. Do not discuss goals or future plans unless they have crystallized to the point that they are "material information" as defined in the Policies. The discussion in this report must be factual, balanced and non-promotional.

General Instructions

- (a) Prepare this Monthly Progress Report using the format set out below. The sequence of questions must not be altered nor should questions be omitted or left unanswered. The answers to the items must be in narrative form. State when the answer to any item is negative or not applicable to the Issuer. The title to each item must precede the answer.
- (b) The term “Issuer” includes the Issuer and any of its subsidiaries.
- (c) Terms used and not defined in this form are defined or interpreted in Policy 1 – Interpretation and General Provisions.

Report on Business

1. Provide a general overview and discussion of the development of the Issuer’s business and operations over the previous month. Where the Issuer was inactive disclose this fact.

Bluma Wellness continues to build on its responsibly scaled growth in the State of Florida, focusing on scaling its operations and sales platform in the month of February. Bluma Wellness operates a licensed, vertically-integrated medical

cannabis enterprise in the State of Florida through its indirect wholly-owned subsidiary, 3 Boys Farm, LLC, doing business as “One Plant Florida” (“**One Plant Florida**”). During the month of February, One Plant Florida averaged sales of 672 ounces of dried medical cannabis flower per retail dispensary and 886,533 mg of distillate/oil sold per retail dispensary. One Plant Florida’s February sales positioned it third in ounces of dried medical cannabis flower sold per retail dispensary and ninth in mg of THC sold per retail dispensary, when compared against all other Medical Marijuana Treatment Centers in the State of Florida, in each case according to information gathered by the Florida Office of Medical Marijuana Use (“**OMMU**”). One Plant Florida expects that it will realize an increased supply of medical cannabis from its Indiantown, Florida cultivation and processing facility, with regular harvests supplying One Plant Florida’s existing and planned new retail dispensaries and delivery hubs throughout the State of Florida.

On February 26, 2021, Bluma Wellness announced that it has filed a management information circular of the Issuer dated as of February 12, 2021 (the “**Circular**”) and related meeting and proxy materials in connection with a special meeting of the shareholders of Bluma Wellness (“**Bluma Shareholders**”) to be held virtually at <https://web.lumiagm.com/294537536>, beginning at 10:00 a.m. (Toronto time) on March 19, 2021 (the “**Meeting**”). The Meeting is being held to consider and approve, among other things, the Issuer’s proposed arrangement (the “**Arrangement**”) with Cresco Labs Inc. (“**Cresco**”) to be completed by way of a plan of arrangement under Division 5 of Part 9 of the *Business Corporations Act* (British Columbia) (the “**Plan of Arrangement**”), pursuant to the arrangement agreement entered into between the Issuer and Cresco on January 13, 2021 (the “**Arrangement Agreement**”). The Meeting will be held in accordance with the terms of an interim order of the Supreme Court of British Columbia (the “**Court**”) obtained on February 11, 2021. Bluma Shareholders of record at the close of business on February 8, 2021 will be entitled to attend and vote at the Meeting.

The Circular and related meeting materials are available on the Issuer’s SEDAR profile at www.sedar.com and have been mailed to Bluma Shareholders of record on February 8, 2021. Holders of the Issuer’s restricted share units will also be sent a copy of the Circular. Bluma Shareholders are encouraged to attend and vote at the Meeting or by proxy prior to the proxy cut-off of 10:00 a.m. (Toronto time) on March 17, 2021. Details on how to attend the Meeting and how to vote are contained in the Circular. The Circular contains important information regarding the Arrangement Agreement and the Arrangement with Cresco, pursuant to which Cresco will acquire all of the issued and outstanding Common Shares. If the Arrangement is completed, Bluma Shareholders will receive 0.0859 of a subordinate voting share of Cresco for each Common Share held, subject to adjustment in accordance with the terms of the Plan of Arrangement.

The completion of the Arrangement is subject to a number of conditions, including but not limited to, approval by the Bluma Shareholders at the Meeting, the approval of the Court, and the receipt of all required regulatory approvals, including of the Canadian Securities Exchange, OMMU, and clearance under the U.S. Hart-Scott-

Rodino Antitrust Improvements Act. If the Arrangement is approved by the requisite majority of Bluma Shareholders at the Meeting, the Issuer will apply to the Court for final approval of the Arrangement on March 25, 2021. Subject to the receipt of all required approvals and the satisfaction or waiver of all applicable conditions, the Arrangement is expected to close by the beginning of the second quarter of 2021.

2. Provide a general overview and discussion of the activities of management.

Management continues to conduct and supervise the day to day management and operation of One Plant Florida's expansion in Florida, including: inventory and supply chain management for the supply of medical cannabis flower from One Plant Florida's Indiantown cultivation and processing facility, retail dispensary and delivery ramp up/expansion, optimization of One Plant Florida's Nexus greenhouse facility at its Indiantown facility, pricing architecture review and optimization, and compliance with all applicable regulatory regimes, in addition to other ongoing activities. Management of the Issuer is engaged in activities to satisfy the conditions for closing the Arrangement, including obtaining necessary regulatory, court and shareholder approvals.

On February 19, 2021, the Issuer announced that it has refiled its interim financial statements for the three and nine months ended September 30, 2020 (the "**Interim Financial Statements**"). The refiled Interim Financial Statements now include a notice, as required by Section 4.3(3)(a) of National Instrument 51-102 – *Continuous Disclosure Obligations*, indicating that the Interim Financial Statements have not been reviewed by an auditor. No other changes have been made to these refiled Interim Financial Statements.

3. Describe and provide details of any new products or services developed or offered. For resource companies, provide details of new drilling, exploration or production programs and acquisitions of any new properties and attach any mineral or oil and gas or other reports required under Ontario securities law.

No new products or services were developed or offered in the month of February.

4. Describe and provide details of any products or services that were discontinued. For resource companies, provide details of any drilling, exploration or production programs that have been amended or abandoned.

No products or services were discontinued in the past month.

5. Describe any new business relationships entered into between the Issuer, the Issuer's affiliates or third parties including contracts to supply products or services, joint venture agreements and licensing agreements etc. State whether the relationship is with a Related Person of the Issuer and provide details of the relationship.

Not applicable.

6. Describe the expiry or termination of any contracts or agreements between the Issuer, the Issuer's affiliates or third parties or cancellation of any financing arrangements that have been previously announced.

Not Applicable.

7. Describe any acquisitions by the Issuer or dispositions of the Issuer's assets that occurred during the preceding month. Provide details of the nature of the assets acquired or disposed of and provide details of the consideration paid or payable together with a schedule of payments if applicable, and of any valuation. State how the consideration was determined and whether the acquisition was from or the disposition was to a Related Person of the Issuer and provide details of the relationship.

Not applicable.

8. Describe the acquisition of new customers or loss of customers.

During the month of February 2021, 15,470 patients were served in Florida by One Plant Florida, with 2,145 of those being new patients.

9. Describe any new developments or effects on intangible products such as brand names, circulation lists, copyrights, franchises, licenses, patents, software, subscription lists and trade-marks.

None.

10. Report on any employee hirings, terminations or lay-offs with details of anticipated length of lay-offs.

None.

11. Report on any labour disputes and resolutions of those disputes if applicable.

Not Applicable.

12. Describe and provide details of legal proceedings to which the Issuer became a party, including the name of the court or agency, the date instituted, the principal parties to the proceedings, the nature of the claim, the amount claimed, if any, if the proceedings are being contested, and the present status of the proceedings.

The Company and its indirect wholly-owned subsidiaries, Cannabis Cures Investments, LLC and 3 Boys Farm, LLC doing business as One Plant Florida, among other parties, are the subject of a contractual claim commenced in circuit court in the State of Florida relating to certain obligations flowing from an Indemnification Agreement entered into by Cannabis Cures Investments, LLC in December 2018. 3 Boys Farm, LLC doing business as One Plant Florida is also the subject of a separate claim commenced in circuit court in the State of Florida by the same plaintiff in the above contractual claim, alleging various breaches of a purported employment agreement between the plaintiff and One Plant Florida.

13. Provide details of any indebtedness incurred or repaid by the Issuer together with the terms of such indebtedness.

Not applicable.

14. Provide details of any securities issued and options or warrants granted.

Security	Number Issued	Details of Issuance	Use of Proceeds
Common Shares	4,728,399	<p>1. On February 3, 2021, the Issuer issued 1,902,421 Common Shares at a deemed price of US\$0.375 per Common Share pursuant to the exercise of outstanding Common Share purchase warrants of the Issuer (each a “Warrant”). The Warrants were exercised pursuant to a cashless exercise term in accordance with the terms of the Warrants.</p> <p>2. On February 3, 2021, the Issuer issued 2,285,978 Common Shares at a deemed price of US\$0.502 per Common Share pursuant to the exercise of outstanding Warrants. The Warrants were exercised pursuant to a cashless exercise term in accordance with the terms of the Warrants.</p> <p>3. On February 17, 2021, the Issuer issued 540,000 Common Shares at a price of US\$1.00 per Common Share pursuant to the exercise of outstanding Warrants.</p>	Working capital and general corporate purposes.

15. Provide details of any loans to or by Related Persons.

Not Applicable.

16. Provide details of any changes in directors, officers or committee members.

None.

17. Discuss any trends which are likely to impact the Issuer including trends in the Issuer’s market(s) or political/regulatory trends.

The medical cannabis marketplace in the State of Florida continues to expand by several thousand patients a week, which offers Bluma Wellness and One Plant Florida the opportunity to serve additional patients and achieve additional market share in the State. Additionally, the broader medical cannabis marketplace is seeing continued demand during the Covid-19 pandemic and One Plant Florida’s delivery network and curbside product pickup options have seen a prolonged period of demand.

[Signature page follows]

Certificate of Compliance

The undersigned hereby certifies that:

1. The undersigned is a director and/or senior officer of the Issuer and has been duly authorized by a resolution of the board of directors of the Issuer to sign this Certificate of Compliance.
2. As of the date hereof there were is no material information concerning the Issuer which has not been publicly disclosed.
3. The undersigned hereby certifies to the Exchange that the Issuer is in compliance with the requirements of applicable securities legislation (as such term is defined in National Instrument 14-101) and all Exchange Requirements (as defined in CNSX Policy 1).
4. All of the information in this Form 7 Monthly Progress Report is true.

Dated March 5, 2021.

Christopher S. Polaszek
Name of Director or Senior
Officer

"Christopher S. Polaszek"
Signature

Corporate Secretary and Chief
Legal Officer
Official Capacity

<i>Issuer Details</i>		For Month End	Date of Report
Name of Issuer		February 2021	YY/MM/D
Bluma Wellness Inc.			2021/03/05
Issuer Address			
1112 N. Flagler Drive			
City/Province/Postal Code		Issuer Fax No.	Issuer Telephone No.
Fort Lauderdale, Florida, 33304		N/A	954-635-5877
Contact Name		Contact Position	Contact Telephone No.
Brady Cobb		CEO	954-635-5877
Contact Email Address		Web Site Address	
legal@oneplant.us		http://www.oneplant.us	